Kornimate/medical-research-clean huggingface dataset:
the study of pharmacological treatment pattern for cannabis-induced psychosis

Conditions: Cannabis

Summary: a cross-sectional and retrospective chart review study was conducted at the princess mother national institute on drug abuse treatment (pmnidat), thailand. all patients who admitted at pmnidat from october 2013 to september 2019 were included. patients aged 18-65 years who met the international classification of disease-10 (icd-10) criteria of cip and had a positive urine test of cannabis were included. cannabis use is a component cause of psychosis.more than half of symptoms of cannabis-induced psychosis (cip) were hallucination, delusion, irritable and anxiety. antipsychotic drug was still a key psychotropic drugs for treatment of cip. however, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics


Eligibility criteria:
inclusion criteria: * patients ≥ 12 years of age * patients who had been diagnosed as cannabis-induced psychosis by international statistical classification of disease and related health problem (icd-10) on 2016 code f12.5 * patients had history of use of cannabis in medical chart * patients had the positive urine screening test of cannabis at the first day of admission exclusion criteria: * patients had psychosis from organic psychosis, defined by diagnosis by icd-10 code f09.6 * unavailable data for evaluate of outcome especially data of drug use, content of drug use or urine screening test * patients who cancel of medical treatment before 7 day after admission.
tracs study: transfusion requirements after cardiac surgery

Conditions: Cardiac Surgery

Summary: blood transfusion is related to worse outcomes and the triggers for red blood cells transfusion are not well defined in cardiac surgery. retrospective studies in cardiac surgery do not show benefits of red blood cell transfusion in reduction of morbidity and mortality in cardiac surgery. there are no prospective studies comparing outcomes between restrictive or liberal strategy in cardiac surgery.this study is a double-blind randomized study comparing clinical outcomes between two strategies of transfusion in cardiac surgery - liberal or restrictive.

blood transfusion is commonly performed in patients submitted to cardiac surgery. however, there are many studies reporting adverse effects of this intervention and final data on benefits are not available. there are no prospective studies in cardiac surgery regarding red blood cell transfusions requirements. there are retrospective studies in cardiac surgery suggesting worse outcomes including higher rates of mortality in patients submitted to red blood transfusion. hematocrit levels around 30% are usually recommended not evidence based. our purpose is to prospectively evaluate two strategies of transfusion in 500 patients submitted to elective cardiac surgery: a liberal strategy - patients receive blood transfusion when hematocrit is lower than 30% since the intraoperative period until the icu discharge; a restrictive strategy - patients receive blood transfusion only when hematocrit is lower than 24%. clinical outcomes, costs and quality of life will be compared.

Eligibility criteria:
inclusion criteria: * all elective primary and redo adult cardiac surgical patients for coronary artery bypass grafting, valve procedure or combined procedures * adults patients * written informed consent exclusion criteria: * age less than 18 years * transplant procedures * emergency procedures * aortic repairs * congenital procedures * previous anemia (hemoglobin lower than 10 g/dl) * previous thrombocytopenia (platelet number lower than 100.000/mm3) * previous known coagulopathy * pregnancy * those unable to receive blood transfusion * patients who refused participation in the study

Keywords: cardiac surgery strategies of transfusion red blood cells liberal restrictive anemia
the effect of green tea and vitamin c on skin health

Conditions: Skin Cancer

Summary: there is little information on the effect of oral bioactive compounds on human skin clinically despite evidence of a beneficial effect from laboratory studies. the aim of this study is to examine the effect of oral bioactive compounds (green tea and vitamin c) on the health of human skin by measuring markers of skin health directly and skin nutrient uptake.

there is little information on the effect of oral catechin, a nutritionally relevant bioactive compound, on skin health in humans in vivo despite considerable evidence for protective effects in experimental studies. vitamin c is essential for skin health and stabilises catechins in the gut lumen. ultraviolet radiation (uvr) in sunlight is a key environmental stressor impacting on skin health. effects include acute inflammation and longer term photodamage. objective: to examine the protective effect of catechin and vitamin c on uvr-induced inflammation. study design (1) a double-blind randomised controlled nutritional study in 50 healthy volunteers. volunteers will receive 3 months dietary supplement with high dose bioactive (n=25),or placebo (n=25). the aim is to quantify the influence of catechin/vitamin c on: 1. uvr-induced inflammation 2. leukocyte infiltration 3. inflammatory mediators 4. markers of photoageing 5. dna damage 6. bioavailability will also be assessed (2) bioavailability of catechin and vitamin c in skin and blood. volunteers will receive active dietary supplement. blood and urine samples will be taken over a period of 6 hours to determine blood bioavailability. skin biopsies will also be taken to assess skin bioavailability. volunteers will then receive 3 months of active dietary supplement followed by repeated sampling.

Eligibility criteria:
inclusion criteria: * healthy adults * sun-reactive skin type i / ii exclusion criteria: * history of skin cancer * history of a photosensitivity disorder * history of a generalised skin disorder * sunbathing (including sunbeds) in the past 3 months * pregnancy * taking photoactive medicine * drink tea \> 2 cups/day * taking nutritional supplements

Keywords: green tea vitamin c ultraviolet radiation inflammation photoageing
evaluation of exoskeleton for upper limb rehabilitation in neurological patients

Conditions: Stroke; Neurologic Disorder

Summary: acquired cerebrovascular trauma is the third most common cause of disability worldwide, resulting in long-term disability, limitation of activities of daily living, and reduced social participation. it is estimated that, within three months of the acute event, a high percentage of patients do not recover full function. 93% of these disabilities concern the upper limb. to induce optimal functional reorganization after the acute cerebrovascular events or neurodegenerative diseases affecting the central nervous system, robotic assistance allows intensive exercises with specific therapeutic purposes. indeed, they enable an intensive, repetitive, and customizable therapeutic program that is in line with the principles underlying motor learning. clinical investigation is needed to assess the efficacy of the proposed new technologies (agree and fexo exoskeleton) and to guide subsequent developmental steps. therefore, an exploratory clinical study is proposed to evaluate usability, tolerability, and safety, as well as to assess the effectiveness of the new technologies. the primary objective of this study is to examine the safety and tolerability of the new active exoskeletons for upper extremity rehabilitation and validate them in a controlled environment. furthermore, efficacy will be examined as the secondary outcome.


Eligibility criteria:
inclusion criteria: * age between 18 and 85 years; * motor deficit of the upper limb induced by neurological diseases (e.g., stroke, multiple sclerosis); * time since the acute event of at least one month; * trunk control test score ≥ 48. exclusion criteria: * global aphasia; * presence of cognitive impairment; * severe unilateral spatial neglect; * box and block test \< 1; * ashworth scale score ≥ 4; * total or severe impairment of visual acuity; * instability of clinical parameters or presence of severe comorbidities; * inadequate anthropometric measurements; * presence of any serious condition that may affect participation in the study (e.g., oncological, hepatic/renal, immune, metabolic/endocrine, psychiatric, respiratory or infectious disorders); * inability to comply with the protocol or to give informed consent.
the impact of physical training under normobaric hypoxia on oxidative stress level, inflammatory state, intestinal damage, and mitochondrial metabolism in young males

Conditions: Hypoxia, Altitude

Summary: * cognitive assessment of the influence of a 4-week proprietary training program under normobaric hypoxia conditions on the levels of inflammatory markers, disturbances in prooxidant-antioxidant balance, degree of intestinal damage, and mitochondrial energy production rate in young sedentary males. * applied objective: development of practical training guidelines utilizing training in normobaric hypoxia conditions to enhance mechanisms related to oxygen transport, adaptive changes within the immune system, body's antioxidant capacity, gut permeability, substrate utilization efficiency, and mitochondrial function for coaches and athletes.


Eligibility criteria:
inclusion criteria: * no known metabolic diseases, no contraindications to physical exercise and no history of high altitude sickness stated in interview. a medical examination (including ecg, blood and urine tests) is required. exclusion criteria: * changes in diet during the experiment, smoking and abuse of alcohol and/or other stimulants.

Keywords: inflammation oxidative stress intestinal damage muscle damage mitochondrial metabolism normobaric hypoxia training
changes in cytokine levels after dextrose injection in stage iv knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: twenty participants with severe arthritis will be enrolled. for the first week participants will either be injected with dextrose or just have fluid withdrawn for testing. the remaining participants will be given dextrose injection at the end of the week. after one week dextrose injections will be given at one, two, three, four, five, and six months. fluid will be withdrawn from the knee at time zero, one week, and three months. the hypothesis is that dextrose injection will cause a change in proteins in the knee consistent with improved repair signals, along with improving knee pain and function. .

participants with stage iv knee osteoarthritis will be evaluated for eligibility and randomized 1 to 1 using an internet randomization method to ensure random allocation. at time zero all participants will receive aspiration of their knees from the suprapatellar pouch of 5.5 ml of synovial fluid for cytokine analysis. after that 10 of the participants will receive injection of 10 ml of 12.5% dextrose. the other 10 will receive no injection after aspiration. pain levels will be measured at time zero, 15 minutes, two hours and 48 hours after aspiration with or without injection to gather information about the time course of analgesia. at one week all participants will receive aspiration of 2.0 ml from the suprapatellar pouch for cytokine analysis, followed by injection of the remaining 10 participants with dextrose 12.5%. pain levels will be measured at the same time intervals to complete evaluation of dextrose analgesia. after two weeks injections will be open label with 10 mills of dextrose 12 and have percent injected at one, two, three, four, five, and six months. at the three month. another 2 ml of synovial fluid will be sent to the laboratory for cytokine analysis.

Eligibility criteria:
inclusion criteria: * knee pain for at least 6 months. * clinically diagnosed knee osteoarthritis. * weight-bearing radiograph consistent with high-grade medial compartment cartilage loss (kellgren-lawrence grading scale level iv). * confirmation of exposed subchondral bone by high-resolution knee ultrasonography. exclusion criteria: * anticoagulation therapy. * inflammatory or post-infectious knee arthritis. * systemic inflammatory conditions. * knee flexion of less than 100 degrees. * knee extension of less than 165 degrees. * any valgus * varus more than 15 degrees. * any knee injection in the past 3 months. * bmi more than 40 * gross synovial folds on ultrasound * elevation of sed rate, c reactive protein, rheumatoid factor or antinuclear antibody.

Keywords: cytokine
hypoxia-guided radiotherapy with cisplatin-etoposide in stage i-iii : small cell lung cancer(sclc)

Conditions: Small Cell Lung Cancer (SCLC)

Summary: since radiation dose escalation to a large volume of tumour inevitably will induce higher toxicity than is currently the case, efforts must be made to limit the volume of tissue irradiated. moreover, the irradiation of larger tumour volumes leads to a lower achievable tumour dose when keeping the normal tissue doses constant. central is thus the question whether it would be possible to limit the volume of tumour to be boosted by selectively escalating the radiation dose to specific disease sites which are theoretically more prone to relapse.

hypoxic imaging with pet scans seems attractive for this purpose as hypoxia is associated with resistance for radiotherapy and approximately 70 % of sclc are severely hypoxic at diagnosis\[2\]. we hypothesize that it might be possible to use a selective boost in these patients to tumor areas which are still hypoxic at the end of the standard chemo-radiotherapy to a dose of 45 gy in 30 fractions in 3 weeks. this way all sclc (small cell lung cancer) patients can receive a safe, but higher dose of radiotherapy to the whole tumor volume, while the most resistant areas receive the highest possible dose. this is a hypothesis generating trial designed to deliver at least the current standard treatment to malignant tissue while defining patient selection criteria for future study.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed stage i-iii small cell lung cancer. who performance status 0-2 * absolute neutrophil count at least 1800/µl and platelets at least 100000/µl and hemoglobin at least 6.2 mmol/l. * adequate renal function: calculated creatinine clearance at least 40 ml/min * adequate hepatic function: total bilirubin ≤ 1.5 x upper limit of normal (uln) for the institution; alt, ast, and alkaline phosphatase ≤ 2.5 x uln for the institution (in case of liver metastases ≤ 5 x uln for the institution) * no previous platinum chemotherapy or topo-isomerase-inhibitors for sclc. * lung function: fev1 at least 30 % and dlco at least 30 % of the age predicted value * no history of prior chest radiotherapy * life expectancy more than 6 months * willing and able to comply with the study prescriptions * 18 years or older * not pregnant or breast feeding and willing to take adequate contraceptive measures during the study * ability to give and having given written informed consent before patient registration * no mixed pathology, e.g. non-small cell plus small cell cancer * no recent (\ 1) (congestive heart failure, infarction) * no uncontrolled infectious disease * no other active malignancy * no major surgery (excluding diagnostic procedures like e.g. mediastinoscopy) in previous 4 weeks * no treatment with investigational drugs in 4 weeks prior to or during this study exclusion criteria: * the opposite of the above

Keywords: toxicity progression survival sclc
clinical performance study of the ultra influenza a&b test using nasal swabs for identifying subjects who are infected with the influenza virus strain type a or type b

Conditions: Influenza, Human

Summary: the clinical performance of the ultra influenza a\&b test will be demonstrated during a clinical trial in which prospectively collected nasal swabs are used in identifying subjects who are infected with the influenza virus strain type a or type b. the ultra influenza a\&b test qualitative results will be compared to "gold standard" viral culture with direct fluorescent antibody (dfa) confirmation techniques using nasal swabs collected from symptomatic subjects. the ultra influenza a\&b test will be performed at clinical laboratory improvement amendments (clia) waived sites by untrained intended users (e.g. nurses, physician assistants, medical assistants, etc.). for viral culture testing with dfa confirmation testing, nasal swab specimen testing will be performed by a designated reference laboratory.


Eligibility criteria:
inclusion criteria: * the subject may be of any age and either gender. * preliminary assessment of the subject by the investigator/designee should be suggestive of influenza virus infection. subject should present with an influenza-like febrile respiratory illness defined as (1) presentation within the last 48 hours of developing a subjective feeling of being feverish and/or a temperature recorded at the clinic within the last 48 hours of greater than or equal to 100.5 f and (2) at least two of the following symptoms: cough, nasal congestion, rhinorrhea, sore throat, headache, myalgia. * written informed consent must be obtained prior to study enrollment. 1. a subject who is 18 years or older must be willing to give written informed consent and must agree to comply with study procedures. 2. the legal authorized representative of a subject who is under the age of 18 must give written informed consent and agree to comply with study procedures. active written assent should be obtained from children of appropriate intellectual age (as defined by the irb). exclusion criteria: * the subject underwent a nasal wash/aspirate as part of standard-of-care testing during this study visit. * the subject is undergoing treatment currently and/or within the past 7 days of the study visit with a nasally administered influenza vaccine (flumist) or with anti-viral medication, which may include but is not limited to amantadine (symmetrel), rimantadine (flumadine), zanamivir (relenza), oseltamivir (tamiflu) or ribavirin. * the subject is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, drug or device, including either treatment or therapy. * the subject has previously participated in this research study.

Keywords: ultra influenza a and b influenza type a influenza type b flu sekisui diagnostics
modified sandwich therapeutic regimen for locally advanced rectal cancer

Conditions: Advanced Rectal Cancer

Summary: in the treatment of locally advanced rectal cancer, the short-term and long-term efficacy of the traditional sandwich regimen has not reached satisfactory efficacy. for this reason, the concept of reducing the dose of postoperative chemotherapy or directly moving forward the full amount of postoperative chemotherapy was proposed, which is called total neoadjuvant therapy (tnt). however, tnt also includes the high toxicity of oxaliplatin in the whole process and the long time interval between the end of radiotherapy and the operation, which leads to fibrosis of the surrounding tissue, which increases the difficulty of surgical resection and makes it difficult to ensure good surgical specimen quality. in addition to this, there are issues that may increase the risk of potential disease progression in patients with poor treatment withdrawal. therefore, appropriately reducing the intensity of chemotherapy and controlling the total duration of preoperative neoadjuvant therapy during radiotherapy is expected to alleviate the side effects of neoadjuvant therapy. here, the investigators synthesized the characteristics of tnt and sandwich regimens and proposed a xelox regimen and capecitabine alternate administration combined with preoperative intensity modulated radiation therapy.


Eligibility criteria:
inclusion criteria: pathological confirmed rectal adenocarcinoma. clinical stage t3-4 or t any n1.with or without mrf positivity, with or without emvi positivity, r0 resection is estimated. no metastasis no signs of intestinal obstruction; or intestinal obstruction has been relieved after proximal colostomy surgery. age ranged from 18 to 75 no previous radiotherapy，surgery and chemotherapy. exclusion criteria: multiple primary tumor cachexy

Keywords: rectal cancer neoadjuvant chemoradiotherapy optimization
behavioral and educational tools to improve epilepsy care

Conditions: Epilepsy

Summary: the long-term goal of this research is to improve seizure control among patients with epilepsy, which has the potential to improve quality of life for thousands of people living with epilepsy and reduce health care utilization, social and economic costs, and epilepsy-related mortalities. participants who are suffering from epilepsy will be randomized to receive usual care (uc), a smartphone-based self-management intervention called management of risks in epilepsy (more), or more + telephone-based motivational interviewing (mi). participants will be followed for 3 months.


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age 2. english- or spanish-speaking 3. partial (focal) or generalized epilepsy (as confirmed with epileptiform activity on an electroencephalogram) 4. poor medication adherence 5. willing and able to use a smartphone (provided by the study) to manage disease. exclusion criteria: 1. known or suspected psychogenic nonepileptic seizures as sole seizure type 2. active psychotic disorder
enamel matrix derivatives on systemic inflammation after periodontal therapy

Conditions: Periodontal Diseases

Summary: the aim of this study is to compare periodontal treatment with or without the adjunct of an enamel matrix derivative in terms of acute-phase responses in healthy patients.

patients with periodontitis will be randomly allocated to two groups. in both groups, periodontal root instrumentation will be performed. in the test group, an additional flapless application of enamel matrix derivatives will be granted for sites with pockets deeper than 5 mm. systemic inflammation as measured through blood testing and local parameters of periodontal health will be measured at baseline and three months after treatment completion.

Eligibility criteria:
inclusion criteria: * good health * no previous periodontal treatment * presence of periodontitis (clinical attachment loss of at least 3 mm in 2 or more non-adjacent teeth) * ability to understand the study procedures and comply with them through the length of the study exclusion criteria: * pregnancy and breast feeding * need for antibiotic treatment during periodontal therapy * chronic infections * systemic diseases * patients who report current smoking over 20 cigarettes per day